{
    "organizations": [],
    "uuid": "1b220f3feb2fb84563ebf149caf16359dc58bc45",
    "author": "",
    "url": "https://www.reuters.com/article/brief-therapeuticsmd-enters-into-negotia/brief-therapeuticsmd-enters-into-negotiations-with-u-s-fda-for-tx-004hr-idUSFWN1RO0FS",
    "ord_in_thread": 0,
    "title": "BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR Reuters Staff \n  TherapeuticsMD Inc: \n* ENTERS INTO LABEL NEGOTIATIONS FOR TX-004HR \n* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR \n* DOES NOT ANTICIPATE PROVIDING SUBSEQUENT UPDATES WITH RESPECT TO LABEL NEGOTIATIONS PRIOR TO PDUFA TARGET ACTION DATE \n* PDUFA TARGET ACTION DATE FOR COMPLETION OF FDAâ€™S REVIEW OF NEW DRUG APPLICATION (NDA) FOR TX-004HR IS MAY 29, 2018 Source text for Eikon:  ",
    "published": "2018-04-11T13:31:00.000+03:00",
    "crawled": "2018-04-11T13:52:51.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "therapeuticsmd",
        "enters",
        "negotiation",
        "fda",
        "reuters",
        "staff",
        "therapeuticsmd",
        "inc",
        "enters",
        "label",
        "negotiation",
        "entered",
        "negotiation",
        "food",
        "drug",
        "administration",
        "regarding",
        "proposed",
        "label",
        "anticipate",
        "providing",
        "subsequent",
        "update",
        "respect",
        "label",
        "negotiation",
        "prior",
        "pdufa",
        "target",
        "action",
        "date",
        "pdufa",
        "target",
        "action",
        "date",
        "completion",
        "fda",
        "review",
        "new",
        "drug",
        "application",
        "nda",
        "may",
        "source",
        "text",
        "eikon"
    ]
}